Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III napabucasin plus FOLFIRI in previously treated metastatic colorectal cancer
2016-001627-31Phase 3Completed
- Sponsor
- Sumitomo Pharma Oncology
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of napabucasin in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Sumitomo Pharma Oncology. Primary endpoint: Overall survival. Started Sep 2016; status: completed.
02
Drugs
napabucasin
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2016-001627-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001627-31.